Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degeneration.

Journal: BMJ open ophthalmology
Published Date: Jun 1, 2025

Abstract

PURPOSE: Age-related macular degeneration (AMD) remains the leading cause of blindness in developed countries. There are many different intravitreal anti-vascular endothelial growth factor (VEGF) drugs available for the treatment of neovascular AMD (nAMD). Unfortunately, not all patients respond equally well to the drugs, and some show recurrences during treatment. Since 01/2024, aflibercept 8 mg represents an additional treatment option and contains a four times higher dosage than the already known aflibercept 2 mg.

Authors

  • Michael Häfner
    St. Elisabeth Hospital, Vienna, Austria.
  • Ben Asani
    Augenklinik und Poliklinik des LMU Klinikums München, München, Deutschland.
  • Franziska Eckardt
    Department of Ophthalmology, LMU University Hospital, LMU Munich, Munich, BY, Germany.
  • Caspar Liesenhoff
    Department of Ophthalmology, LMU University Hospital, LMU Munich, Munich, BY, Germany.
  • Alexander Kufner
    Department of Ophthalmology, LMU University Hospital, LMU Munich, Munich, BY, Germany.
  • Jakob Siedlecki
    Department of Ophthalmology, LMU University Hospital, LMU Munich, Munich, BY, Germany.
  • Benedikt Schworm
    Department of Ophthalmology, LMU University Hospital, LMU Munich, Munich, BY, Germany.
  • Siegfried Priglinger
    Department of Ophthalmology, Ludwig-Maximilians-University Munich, Germany.
  • Johannes Benedikt Schiefelbein
    Department of Ophthalmology, LMU University Hospital, LMU Munich, Munich, BY, Germany Johannes.Schiefelbein@med.uni-muenchen.de.

Keywords

External Resources

Popular Topics
Recent Journals